Alpha-synuclein and protein degradation pathways in Parkinson's disease: A pathological feed-back loop

Experimental Neurology

Volumn 247, Issue , 2013, Pages 308-313

  Martinez Vicente, Marta ^a   Vila, Miquel ^a,b,c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PROTEASOME; RAPAMYCIN; TREHALOSE; UBIQUITIN;

CELLULAR DISTRIBUTION; CHAPERONE-MEDIATED AUTOPHAGY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOCYTOSIS; FEEDBACK SYSTEM; HUMAN; LYSOSOME; MACROAUTOPHAGY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NOTE; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN UNFOLDING; SIGNAL TRANSDUCTION; SOLUBILITY;

FEMALE; HUMANS; MALE; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84881376026     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.03.005     Document Type: Note

References (80)

1. Alvarez-Erviti L., Rodriguez-Oroz M.C., Cooper J.M., Caballero C., Ferrer I., Obeso J.A., Schapira A.H. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 2010, 67:1464-1472.
2. Ancolio K., Alves da Costa C., Ueda K., Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 2000, 285:79-82.
3. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
4. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., Mayer R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 2008, 28:8189-8198.
5. Bennett E.J., Bence N.F., Jayakumar R., Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 2005, 17:351-365.
6. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., Stenmark H., Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 2005, 171:603-614.
7. Bohley P., Seglen P.O. Proteases and proteolysis in the lysosome. Experientia 1992, 48:151-157.
8. Bove J., Martinez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 2011, 12:437-452.
9. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 2006, 60:260-264.
10. Chen Q., Thorpe J., Keller J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 2005, 280:30009-30017.
11. Crews L., Spencer B., Desplats P., Patrick C., Paulino A., Rockenstein E., Hansen L., Adame A., Galasko D., Masliah E. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 2010, 5:e9313.
12. Cuervo A.M. Autophagy: many paths to the same end. Mol. Cell. Biochem. 2004, 263:55-72.
13. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
14. Dehay B., Bove J., Rodriguez-Muela N., Perier C., Recasens A., Boya P., Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 2010, 30:12535-12544.
15. Dice J. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem. Sci. 1990, 15:305-309.
16. Dice J. Lysosomal Pathways of Protein Degradation 2000, Landes Bioscience, Austin, TX.
17. Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B.T., McLean P.J., Unni V.K. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 2011, 31:14508-14520.
18. Emmanouilidou E., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 2010, 31:953-968.
19. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 2009, 78:477-513.
20. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 2003, 23:8955-8966.
21. Gallastegui N., Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem. Sci. 2010, 35:634-642.
22. Huang Q., Figueiredo-Pereira M.E. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 2010, 15(11):1292-1311.
23. Huotari J., Helenius A. Endosome maturation. EMBO J. 2011, 30:3481-3500.
24. Jariel-Encontre I., Bossis G., Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. Biochim. Biophys. Acta 2008, 1786:153-177.
25. Kalia L.V., Kalia S.K., Chau H., Lozano A.M., Hyman B.T., McLean P.J. Ubiquitinylation of alpha-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One 2011, 6:e14695.
26. Kaushik S., Cuervo A.M. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012, 22:407-417.
27. Kaushik S., Massey A.C., Mizushima N., Cuervo A.M. Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. Mol. Biol. Cell 2008, 19:2179-2192.
28. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 2003, 85:115-122.
29. Kirkin V., Lamark T., Sou Y.S., Bjorkoy G., Nunn J.L., Bruun J.A., Shvets E., McEwan D.G., Clausen T.H., Wild P., Bilusic I., Theurillat J.P., Overvatn A., Ishii T., Elazar Z., Komatsu M., Dikic I., Johansen T. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol. Cell 2009, 33:505-516.
30. Kirkin V., McEwan D.G., Novak I., Dikic I. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
31. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
32. Koga H., Kaushik S., Cuervo A.M. Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res. Rev. 2011, 10:205-215.
33. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., Mizushima N., Iwata J., Ezaki J., Murata S., Hamazaki J., Nishito Y., Iemura S., Natsume T., Yanagawa T., Uwayama J., Warabi E., Yoshida H., Ishii T., Kobayashi A., Yamamoto M., Yue Z., Uchiyama Y., Kominami E., Tanaka K. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
34. Kraft C., Peter M., Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat. Cell Biol. 2010, 12:836-841.
35. Kristiansen M., Deriziotis P., Dimcheff D.E., Jackson G.S., Ovaa H., Naumann H., Clarke A.R., van Leeuwen F.W., Menendez-Benito V., Dantuma N.P., Portis J.L., Collinge J., Tabrizi S.J. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 2007, 26:175-188.
36. Lee H.J., Khoshaghideh F., Patel S., Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 2004, 24:1888-1896.
37. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., Jensen P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279:12924-12934.
38. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
39. Mak S.K., McCormack A.L., Manning-Bog A.B., Cuervo A.M., Di Monte D.A. Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 2010, 285:13621-13629.
40. Maraganore D.M., Lesnick T.G., Elbaz A., Chartier-Harlin M.C., Gasser T., Kruger R., Hattori N., Mellick G.D., Quattrone A., Satoh J., Toda T., Wang J., Ioannidis J.P., de Andrade M., Rocca W.A. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 2004, 55:512-521.
41. Martinez-Vicente M., Sovak G., Cuervo A.M. Protein degradation and aging. Exp. Gerontol. 2005, 40:622-633.
42. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P.T., Sulzer D., Cuervo A.M. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 2008, 118:777-788.
43. Martins-Branco D., Esteves A.R., Santos D., Arduino D.M., Swerdlow R.H., Oliveira C.R., Januario C., Cardoso S.M. Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness? Exp. Neurol. 2012, 238(2):89-99.
44. Massey A.C., Kaushik S., Sovak G., Kiffin R., Cuervo A.M. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5805-5810.
45. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002, 13:1437-1441.
46. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
47. Mullins C., Bonifacino J.S. The molecular machinery for lysosome biogenesis. Bioessays 2001, 23:333-343.
48. Muntane G., Ferrer I., Martinez-Vicente M. Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 2012, 200:106-119.
49. Nedelsky N.B., Todd P.K., Taylor J.P. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim. Biophys. Acta 2008, 1782:691-699.
50. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P.J., Haass C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 2000, 275:390-397.
51. Pandey U.B., Batlevi Y., Baehrecke E.H., Taylor J.P. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy 2007, 3:643-645.
52. Pankiv S., Clausen T.H., Lamark T., Brech A., Bruun J.A., Outzen H., Overvatn A., Bjorkoy G., Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 2007, 282:24131-24145.
53. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
54. Pickart C.M., Cohen R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol. 2004, 5:177-187.
55. Ravikumar B., Sarkar S., Rubinsztein D.C. Clearance of mutant aggregate-prone proteins by autophagy. Methods Mol. Biol. 2008, 445:195-211.
56. Rideout H.J., Lang-Rollin I.C., Savalle M., Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 2005, 93:1304-1313.
57. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 2001, 78:899-908.
58. Rott R., Szargel R., Haskin J., Bandopadhyay R., Lees A.J., Shani V., Engelender S. Alpha-synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18666-18671.
59. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., Shimohama S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 2004, 279:10710-10719.
60. Settembre C., Di Malta C., Polito V.A., Garcia A.M., Vetrini F., Erdin S., Erdin S.U., Huynh T., Medina D., Colella P., Sardiello M., Rubinsztein D.C., Ballabio A. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332:1429-1433.
61. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
62. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., Troconso J.C., Dawson V.L., Dawson T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
63. Shin Y., Klucken J., Patterson C., Hyman B.T., McLean P.J. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 2005, 280:23727-23734.
64. Shringarpure R., Grune T., Mehlhase J., Davies K.J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 2003, 278:311-318.
65. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 2003, 278:11753-11759.
66. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., Masliah E. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 2009, 29:13578-13588.
67. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21:9549-9560.
68. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson L., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 2001, 10:919-926.
69. Tetzlaff J.E., Putcha P., Outeiro T.F., Ivanov A., Berezovska O., Hyman B.T., McLean P.J. CHIP targets toxic alpha-synuclein oligomers for degradation. J. Biol. Chem. 2008, 283:17962-17968.
70. Tofaris G.K., Kim H.T., Hourez R., Jung J.W., Kim K.P., Goldberg A.L. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17004-17009.
71. Tsvetkov P., Reuven N., Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ. 2010, 17:103-108.
72. Vogiatzi T., Xilouri M., Vekrellis K., Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 2008, 283:23542-23556.
73. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
74. Winslow A.R., Chen C.W., Corrochano S., Acevedo-Arozena A., Gordon D.E., Peden A.A., Lichtenberg M., Menzies F.M., Ravikumar B., Imarisio S., Brown S., O'Kane C.J., Rubinsztein D.C. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 2010, 190:1023-1037.
75. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
76. Xie W., Li X., Li C., Zhu W., Jankovic J., Le W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J. Neurochem. 2010, 115:188-199.
77. Xilouri M., Brekk O.R., Stefanis L. Alpha-Synuclein and Protein Degradation Systems: A Reciprocal Relationship. Mol. Neurobiol. 2013, 47(2):537-551.
78. Xilouri M., Vogiatzi T., Vekrellis K., Park D., Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009, 4:e5515.
79. Yamamoto A., Simonsen A. The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Neurobiol. Dis. 2011, 43:17-28.
80. Yu W.H., Dorado B., Figueroa H.Y., Wang L., Planel E., Cookson M.R., Clark L.N., Duff K.E. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am. J. Pathol. 2009, 175:736-747.